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Cisapride decreases gastric content aspiration in mechanically
ventilated patients
John Pneumatikos, Basil Koulouras, Christ Frangides, Dian Goe
and George Nakos
Objective:  To determine the effect of the prokinetic agent cisapride in the
prevention of aspiration of gastric contents.
Design: A prospective randomized two-period crossover study.
Setting: Fourteen-bed polyvalent intensive care unit in a University Hospital.
Patients: Eighteen intubated, mechanically ventilated patients who were seated
in a semirecumbent position were studied.
Method: Tc-99m sulfur colloid (80 megabecquerels) was administered via
nasogastric tube on 2 consecutive days. Patients randomly received cisapride
(10mg, via nasogastric tube) one day and a placebo the other. Bronchial
secretions were obtained before and for 5 consecutive h after Tc-99m
administration. The radioactivity was measured in a standard amount (1ml) of
bronchial fluid using a gamma counter and expressed as counts per min (cpm)
after correction for decay.
Results: Sixteen out of 18 (88%) patients had increased radioactivity in
bronchial secretions. The radioactivity increased over time both with and without
cisapride, although it was lower in patients receiving cisapride than in those
receiving a placebo. The cumulative bronchial secretion radioactivity obtained
when patients received cisapride was significantly lower than when patients
received a placebo: 7540±5330 and 21965±16080cpm, respectively
(P<0.05).
Conclusion: Our results suggest that aspiration of gastric contents exists even
in patients who are kept in a semirecumbent position. Moreover, cisapride
decreases the amount of gastric contents aspiration in intubated and
mechanically ventilated patients and may play a role in the prevention of
ventilator associated pneumonia. Cisapride, even with the patient in the
semirecumbent position, did not completely prevent gastric content aspiration.
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Introduction
The aspiration of gastric contents induces or exacerbates
bronchoconstriction and it is the most commonly recog-
nized pathogenic factor for the development of pneumonia,
especially in ventilator-associated pneumonia (VAP) [1,2].
The incidence of aspiration of gastric contents is high in
intensive care unit (ICU) patients and even higher in
intubated and mechanically ventilated patients. Gastroin-
testinal tract dysmotility is a relatively common condition
in critically ill patients and is associated with gastric con-
tents aspiration [3,4]. Additional risk factors for gastric
content aspiration included enteral feeding, naso or oral-
gastric tubes and position of the patients. Enteral feeding
via a nasogastric tube may also result in increased gastric
volume, reflux and Gram-negative bacterial overgrowth
in the stomach [5]. Wide bore nasogastric tubes them-
selves probably impair the function of the lower
esophageal sphincter, thereby facilitating aspiration and
bacterial contamination of the tracheobronchial tree [6].
Moreover, an important risk factor in causing the aspira-
tion of gastric contents seems to be the supine position. A
semirecumbent position of mechanically ventilated
patients could help in part to prevent the aspiration of
gastric contents into airways, but aspiration still remains a
problem [7]. Orozco-Levi and colleagues [8] showed a
significant increase in radioactivity count in oropharyn-
geal contents after Tc99m isotope instillation through
nasogastric tube. This gastroesophageal reflux was irre-
spective of body position. In contrast, the radioactivitycount values in bronchial secretions were higher in the
supine position than in semirecumbency, which suggests
that the semirecumbent position helps prevent in part
gastric content aspiration. Apart from position, agents,
such as erythromycin and cisapride, increase the gastric
motility and they could accelerate gastric emptying and
prevent gastric aspiration [9,10].
Cisapride is a very effective prokinetic agent that acts by
increasing the physiological release of acetylcholine from
the postganglionic nerve endings of the myenteric plexus
without any associated dopamine antagonism [10].
In this study, we assessed the effect of cisapride in the
prevention of pulmonary aspiration of gastric contents in
mechanically ventilated patients maintaining the benefit
of a semirecumbent position.
Materials and methods
Patients
Eighteen mechanically ventilated patients (15 men and
three women, mean age 52.33±17.90 years) were included
in this study. The protocol was approved by the Medical
Ethics Committee of The University Hospital of Ioannina
and consent was obtained from the patients’ relatives.
Patients with gastrectomy, ileus, respiratory infections,
sepsis and hemodynamic instability (low blood pressure
needing high doses of inotropes, or wide fluctuation of
blood pressure over time) were excluded from the study.
The demographic data and the underlying clinical condi-
tions of these patients are summarized in Table 1.
Protocol
All patients had a 5mm diameter nasogastric tube in place for
enteral nutritional support and received sucralfate 2g twice
daily for stress ulcer prophylaxis. The position of the nasogas-
tric tube was radiographically checked before the study.
Sedation and all the other medications were kept unchanged
throughout the study (Table 1). Nobody was given paralytic
agents, antibiotics or inotropes. The enteral nutrition and
other medications via nasogastric tube were withheld 8h
before the onset and during the study. The body position of
the patients was semirecumbent at a 45 degree angle, and
they were put in this position at least 8h before the study.
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Table 1
Patient characteristics
No Sex Age Diagnosis APACHE II Medications MV Outcome
1 F 58 SBH 22 Midazolam 5 S
2 M 54 ICH 20 – 5 D
3 M 54 COPD 28 Midazolam 5 D
4 F 70 COPD 30 Propofol 8 S
5 M 48 Head injury 24 Fentanyl, Midazolam 10 S
6 M 19 GBS 14 Fentanyl 5 S
7 M 40 Head injury 29 Fentanyl, Midazolam 6 D
8 M 67 Head injury 28 Fentanyl, Midazolam 7 S
9 M 76 ICH 28 Midazolam 6 D
10 M 41 Drug overdose 12 – 4 S
11 M 74 ICH 25 Midazolam, Fentanyl 4 D
12 M 74 Cardiac failure 27 Lorazepam 4 D
13 F 64 ICH 25 Midazolam 6 S
14 M 25 Head injury 17 Lorazepam, Fentanyl 5 S
15 M 26 Trauma 22 Fentanyl 5 S
16 M 55 Head injury 24 Propofol 8 S
17 M 62 ICH 27 – 6 S
19 M 35 Head injury 19 Propofol, Fentanyl 8 S
Mean 52 23 6
SD 17 5 1.7
M, male; F, female; S, survival; D, death; ICH, intracerebral hemorrhage; GBS, Guillain Barr syndrome; SBH, subarachnoid brain hemorrhage;
COPD, chronic obstructive pulmonary disease; MV, days of mechanical ventilation.All patients were intubated and mechanically ventilated
with an assist-control mode. A low level of positive end-
expiratory pressure (PEEP) was used (PEEP: 5±1.7cmH2O).
The volume, pressure and the leaking of the cuff of the
endotracheal tube was checked, before and at the end of
every day of the study. The minimal volume and pressure
necessary to prevent air leaking around the cuff were
used. The study lasted 2 consecutive days for each
patient. Eighteen hours before the study, the patients
received, at 6h intervals, a cisapride suspension (Alimix,
Janssen Pharmaceutica, Beerse, Belgium; 1mg/ml) in a
dose of 10mg, or a placebo given as a bolus randomly via
nasogastric tube. The next morning, 60megabecquerels
of Tc99m sulfur colloid were carefully administered via
the tube as described by Chernow and colleagues [11].
Bronchial secretions were taken at zero time (baseline
radioactivity) and then once an hour for 5 consecutive h.
The secretions were taken in a sterile container by
bronchial suction. The suction catheter was placed at the
level of the carina. The distance of the carina from the tip
of the endotracheal tube was measured on a chest X-ray.
Just after the end of this procedure, patients who had pre-
viously received cisapride were given placebo and vice
versa. On the second day, the procedure was repeated in
the same way. Blood samples were taken from the first
five patients in the study, before and 5h after isotope
instillation and checked for radioactivity. Just before
starting the procedure, bronchial secretion, oropharyngeal
and gastric samples were taken for microbiological cul-
tures. A gentle suction of gastric content was performed
just before the administration of the isotope.
Measurements
The activity of Tc99m was measured, using a gamma
counter (Gamma Counting system, Crystal TM II, 5400
Series, Packard Instrumental Company), in a standard
amount (1ml) of bronchial secretions. The amount of
radioactivity is expressed as counts per min (cpm) after
correction for decay according to the equation of radioac-
tive decay law:
N=N 0.e–lt
where N0 is the number of parent nuclei present at t=0,
N is the number remaining nuclei at time t, l is a con-
stant of proportionality, called the decay constant, which
is different for different isotopes and e is the base of
natural logarithm [12].
During the procedure, monitoring was performed with a
two-lead electrocardiogram (ECG) and a 12-lead ECG was
performed before and soon after the end of every procedure.
Statistics
The differences between groups were tested for signifi-
cance by analysis of variance (ANOVA) test for repeated
measures. Results are expressed as mean±SD. A P value
less than 0.05 was considered significant.
Results
Sixteen out of 18 patients (88%) demonstrated an
increased radioactivity in bronchial secretions and it
increased over time both in patients receiving cisapride or
placebo. When patients received cisapride, the radioactiv-
ity increased from 120±18 cpm (baseline radioactivity at
zero time) to 1930±1340 cpm at the fifth hour (P<0.05).
When patients received a placebo the radioactivity
increased from 115±22 cpm (baseline radioactivity at the
zero time) to 6825±5100 cpm 5h later (P<0.01). There
was no significant difference in baseline radioactivity of
bronchial secretions whether the patients were given cisa-
pride or placebo. The change in radioactivity of bronchial
secretions over time is demonstrated in Fig 1. The differ-
ence in radioactivity during cisapride and placebo admin-
istration became statistically significant after the third
hour (P<0.05). The cumulative bronchial secretion
radioactivity obtained when patients received cisapride
was significantly lower than when patients received a
placebo (7540±5330 and 21965±16080cpm, respectively;
P<0.05; Fig 2).
The microbiological cultures showed that 10 patients had
identical microorganisms colonizing the stomach, oropharyn-
geal area and bronchus. Five patients had the same microor-
ganisms only in the oropharyngeal content and bronchial
secretion, and different ones in the gastric content. Three
patients had different microorganisms in stomach, orophar-
ynx and bronchus. Two of the studied patients developed
VAP during their stay in ICU; both patients had the
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Figure 1
The radioactivity of bronchial secretions over time. The values at zero
time represent the baseline radioactivity. Asterisk (*) denotes statistical
significance between cisapride and placebo.stomach, oropharynx and bronchus colonized with the
causative bacteria of VAP, which were detected by quantita-
tive cultures of protected brush specimens.
There was no significant difference in cuff pressure
between measurements before and at the end of the study.
There was no difference in the blood radioactivity before
and 5h after isotope administration, as it was the same as
the background radioactivity.
No side effects of cisapride were observed during this
study. No cardiac arrhythmia or QT interval prolongation
was noted.
Discussion
This study demonstrates that cisapride significantly
reduced the pulmonary aspiration of gastric contents in
mechanically ventilated patients although the conven-
tional protective methods, such as semirecumbent posi-
tion and regular checking of cuff leaking, even with
cisapride administration are not sufficient to prevent
gastric content aspiration completely.
In critically ill patients receiving mechanical ventilation
gastrointestinal motility is often impaired [3,4]. The
precise mechanism leading to this gastroparesis is still
unknown. Medications such as opiates and dopamine
[13,14], hyperglycemia [15] or increased intracranial pres-
sure [16] have all been shown to depress the antral motor
activity in experimental or clinical conditions. This situa-
tion favors not only gastroesophageal reflux but also duo-
denogastric reflux, thereby promoting the colonization of
the stomach with gastric Gram negative pathogens [17,18].
Enteral nutrition in patients with inadequate gastric emp-
tying can increase the risk of aspiration, and expand the
size of the gastric bacterial reservoir by increasing the
gastric volume and the pH. Today most investigators
agree that gastric colonization with potentially pathogenic
microorganisms is important in the pathogenesis of VAP
[17,19,20]. Moreover, nasogastric tubes themselves proba-
bly impair the function of the lower esophageal sphincter
thereby promoting aspiration. In addition, the supine posi-
tion of patients promotes aspiration and the semirecum-
bent position helps minimize the aspiration of gastric
contents to lower airways [7,8].
Our results showed that aspiration in mechanically venti-
lated patients occurs even when they are kept in a semire-
cumbent position. The administration of cisapride
significantly decreases aspiration in these patients. A prop-
erly inflated cuff was insufficient to prevent aspiration to
lower airways. The incidence of gastric content aspiration
in our group of patients was very high. One explanation
could be the high percentage of neurological diseases,
which are included in our patient population, because
severe head injury has been associated with impaired
gastric emptying [16]. Another cause of the high incidence
of aspiration could be the sedation received by the major-
ity of the patients. There is no clear explanation for the
absence of gastric content aspiration in two patients. It is
noteworthy, though, that one of them did not receive
sedation and the other was given low-dose (5mg/h) mida-
zolam. Both survived, and their age, APACHE II score
and the days of mechanical ventilation at the day of the
study were equivalent to those of the other patients.
These findings are in agreement with other investigators
who found that cisapride prevents the morphine-induced
delay in gastric emptying [21]. It also significantly acceler-
ates gastric emptying both in patients with gastro-
esophageal reflux disease and in patients with delayed
gastric emptying caused by idiopathic or postsurgical
reasons [22]. It has also been suggested that cisapride can
minimize the risk of aspiration pneumonia in patients with
long-term enteral feeding [23]. In critically ill patients
with gastric dilatation and functional gastric paralysis the
administration of cisapride showed a clinical benefit
[24,25]. Moreover, cisapride increases the lower esopha-
geal sphincter pressure in normal volunteers and in
patients with reflux disease [26]. The velocity of transit in
the esophagus remains unchanged with cisapride, but an
increase in distal peristalsis is noted [27].
Oral cisapride usually has few side effects. Nevertheless,
cardiac arrhythmias, especially torsade de pointes, and
prolonged QT intervals with a potentially fatal outcome
have been described in patients with concomitant use of
medication that is metabolized by the cytochrome P-450
3a4 isoenzyme, eg imidazole antibiotics or macrolides [28].
Cisapride should be administered with caution in patients
42 Critical Care 1999, Vol 3 No 1
Figure 2
The cumulative radioactivity of bronchial secretions with and without
cisapride.who are on any medication known to prolong QT interval
and in those with renal insufficiency, a history of arrhyth-
mia or cardiac disease. None of our patients received any
of the above medications and, possibly for this reason, no
side effects were noted during the period of cisapride
administration.
Conclusion
In summary, our results suggest that cisapride decreases
the risk of aspiration of gastric contents in intubated and
mechanically ventilated patients who are kept in a semi-
recumbent position. Conventional protective methods
though, such as the semirecumbent position and regular
checking of cuff leaking, even with cisapride administra-
tion are not sufficient to prevent gastric content aspiration
completely. Further studies are needed to establish if this
drug helps in the prevention of ventilator associated pneu-
monia, bronchitis or bronchoconstriction.
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